Who Is Eligible for TAVI/TAVR? Indications, Benefits, and Risk Factors Explained

Who Is Eligible for TAVI/TAVR? Indications, Benefits, and Risk Factors Explained

TAVI (transcatheter aortic valve implantation) / TAVR (transcatheter aortic valve replacement) is a catheter-based way to replace a diseased aortic valve—most often for severe aortic stenosis—without traditional open-heart surgery.


The important word in TAVI eligibility is eligible: the procedure is highly effective in the right patient, and a bad fit in the wrong anatomy or clinical context.


Clinicians usually decide candidacy through a Heart Team (imaging cardiology + interventional cardiology + cardiac surgery), because “valve replacement” is not just a one-time procedure—it’s a lifetime strategy.


The 2025 ESC/EACTS guidance emphasizes Heart Team decision-making, Heart Valve Centres for complex cases, and choosing the mode of intervention using clinical factors, anatomy, procedural considerations, life expectancy, and lifetime management.


Step 1: Do you actually need a valve replacement?


Most TAVR candidates have severe aortic stenosis with symptoms. Think of the aortic valve as the heart’s exit door.


When it becomes stiff and narrow, the heart must generate higher pressure to push blood through. Symptoms often appear when demand rises.


You don’t need a dramatic episode to qualify. A common pattern is subtle: you notice that a staircase that felt routine now forces you to stop halfway, or you feel chest tightness only when walking fast, or you get dizzy on exertion.


In aortic stenosis, that “exertion-only” pattern matters because it signals the heart is hitting a flow bottleneck.


Guidelines strongly support intervention in symptomatic severe aortic stenosis, and they also include selected asymptomatic scenarios (for example, certain high-risk features or LV dysfunction) where early intervention can be considered.


Step 2: Who is more likely to be offered TAVI vs open surgery?


Eligibility is not just “old people get TAVR.” Age and life expectancy are major inputs, but not the only ones.


Age thresholds (why they show up so often)




How to read this as a patient: age thresholds are shorthand for two realities—(1) surgical recovery burden, and (2) long-term valve planning (durability, future access to coronary arteries, and the likelihood of needing another valve procedure later).


Surgical risk and “frailty” (the part age doesn’t capture)


Two people can be 72 and have totally different risk profiles. Heart Teams look at:


  1. prior heart surgery or chest radiation
  2. severe lung disease
  3. severe kidney disease
  4. major mobility limitations or frailty
  5. other conditions that make open surgery disproportionately risky

This is why you’ll sometimes see a relatively younger person being steered toward TAVI (because surgery is risky), and an older person being steered away (because anatomy is hostile or the expected benefit is limited).


Step 3: Anatomy decides more than most people expect


Even if you’re a perfect clinical candidate, heart valve replacement criteria for TAVI include one non-negotiable: the new valve must be implantable safely.


CT planning is central


Cardiac CT is widely treated as the gold standard for:


  1. annulus sizing (choosing valve size)
  2. assessing peripheral access (can the catheter pass safely?)
  3. estimating risk of coronary occlusion
  4. predicting procedural angles

If you want to visualize why this matters, picture trying to deliver a folded umbrella through a narrow, calcified pipe without scraping the pipe wall.


That’s why teams care about vessel diameter, calcification, and tortuosity—not because they like measurements, but because access complications can be serious.


Key anatomical “yes/no” considerations





Specific indications that often qualify as “TAVR candidates”


1) Severe symptomatic aortic stenosis (the main indication)


This is the core group: symptoms + severe stenosis + anatomy that supports a safe implant.


2) “Valve-in-valve” for a failed surgical tissue valve


If someone had a bioprosthetic surgical valve years ago and it degenerates, a valve-in-valve TAVR can sometimes avoid redo open surgery. This approach is well-established and has specific planning challenges (especially coronary obstruction risk).


3) Severe aortic regurgitation when surgery isn’t an option (selected cases)


ESC 2025 notes TAVI may be considered for severe aortic regurgitation in symptomatic patients deemed ineligible for surgery, if anatomy is suitable.


TAVI benefits: what patients typically gain (and what they don’t)


When people say “minimally invasive heart surgery,” what they usually mean is: no sternotomy, less surgical trauma, and often a faster functional recovery. Cleveland Clinic describes TAVR as a minimally invasive alternative to open-heart surgery for replacing the aortic valve.


TAVI benefits commonly include:


  1. symptom relief (breathlessness, fatigue, exertional dizziness often improve)
  2. shorter hospital stay in many patients
  3. faster return to basic mobility compared with sternotomy recovery

What it does not guarantee:


  1. “No risks”
  2. “No follow-up”
  3. “No future valve decisions” (especially in younger patients)

Risk factors and complications: what can make TAVR higher-risk


This is where eligibility becomes nuanced: some factors push you toward TAVR instead of surgery, while simultaneously increasing the technical risk of TAVR.


1) Conduction problems and pacemaker requirement


TAVR can disturb the heart’s electrical system because the valve sits close to conduction tissue.


A consistent risk factor is pre-existing right bundle branch block (RBBB); multiple reviews highlight baseline conduction disease as a major predictor of needing a permanent pacemaker after TAVR.


A useful way to frame this: if your pre-procedure ECG already shows a “fragile wiring setup,” the procedure can be the last nudge that produces slow heart block requiring pacing.


2) Paravalvular leak (PVL)


PVL is leakage around the valve frame rather than through the valve leaflets. Predictors include heavy calcification, annular eccentricity, bicuspid valves, and device/anatomy interaction.


PVL is not just a technical footnote—moderate/severe PVL has been associated with worse outcomes, which is why sizing and imaging precision matter.


3) Coronary obstruction (rare, high-stakes)


Coronary obstruction is uncommon but dangerous. Risk increases with low coronary ostia, shallow sinuses of Valsalva, bulky calcification, and especially valve-in-valve procedures.


This is exactly why CT planning focuses on coronary heights and root geometry rather than treating them as “nice-to-know.”


4) Vascular access complications


Risk rises when femoral/iliac vessels are small, heavily calcified, tortuous, or when peripheral artery disease is present.


Patient factors commonly cited include peripheral vascular disease and female sex; procedural factors include sheath-to-artery sizing and operator/centre experience.


5) Kidney injury, bleeding, stroke


These risks depend on baseline kidney function, contrast load, vascular complexity, and overall clinical fragility. (This is also why Heart Valve Centres and Heart Team selection are emphasized in ESC guidance for complex cases.)


Read: PSARA Registration Guide: License, Eligibility, Process & Benefits


A practical “eligibility checklist” you can use in consultations


Instead of asking only “Am I eligible for TAVI?”, ask questions that force clarity:


  1. Is my valve disease severe enough to require replacement now?
  2. What’s my main driver: symptoms, LV function, or high-risk features?
  3. Does CT show transfemoral access is safe and the annulus is suitable?
  4. What’s my pacemaker risk (baseline ECG, RBBB, valve type considerations)?
  5. If I’m younger, what’s the lifetime valve strategy (today + next 10–20 years)?

Conclusion


TAVI eligibility is a three-part decision: (1) you need an aortic valve replacement (usually severe aortic stenosis with symptoms), (2) TAVI offers the best balance of benefit vs risk for your age, life expectancy, and surgical risk profile, and (3) your anatomy supports a safe implant—


confirmed largely through CT-based planning. Current guidance underscores Heart Team decision-making and lifetime management: ESC 2025 recommends TAVI for many patients ≥70 with suitable anatomy, while generally favoring


surgery for low-risk patients <70, and ACC/AHA guidance uses different age/life-expectancy thresholds but the same shared-decision principle.